AI Article Synopsis

  • The study evaluated the effects of lenvatinib treatment on liver function in older patients with advanced hepatocellular carcinoma (HCC).
  • It involved 119 patients with a median age of 72, finding that those who maintained liver function had better overall survival rates.
  • Results indicated that older patients were more likely to experience liver function deterioration after treatment, suggesting the need for potential dose adjustments for this age group.

Article Abstract

Background: The age of patients with advanced hepatocellular carcinoma (HCC) eligible for molecular-targeted drug treatment is increasing. We assessed liver function after lenvatinib administration according to age in patients with advanced HCC.

Patients And Methods: In this retrospective, multicenter, observational study, we reviewed the records of patients with HCC who received lenvatinib treatment (March 2018-March 2020). Liver function was measured using the Albumin-Bilirubin Index (ALBI).

Results: Of 119 patients, with a median age of 72.0 years, median overall survival was 15.3 months. Overall survival was significantly better in the group which maintained liver function (p=0.02). Older age (≥72 years) was associated with liver-function deterioration within 8 weeks (odds ratio=2.47, 95% confidence interval=1.06-5.75, p=0.035). The ALBI score was significantly higher in the older group at 4 and 8 weeks after lenvatinib administration.

Conclusion: Lenvatinib administration was more likely to adversely affect liver function in older patients; dose adjustment should be considered in such patients.

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14970DOI Listing

Publication Analysis

Top Keywords

liver function
20
function older
8
older patients
8
hepatocellular carcinoma
8
age patients
8
patients advanced
8
lenvatinib administration
8
patients
7
liver
5
lenvatinib
5

Similar Publications

Cellulite is an aesthetically distressing skin condition occurring in 80-90% of females and manifesting as dimples and depressions, producing an uneven surface to the skin. Our aim was to evaluate the effect of combined oral consumption of two dietary supplements based on chokeberry and tart cherry juices over a period of 32 days on cellulite reduction. Twenty women aged 21-49 with a cellulite grade of 1-2 according to the Nurnberger-Muller scale were participating in the study.

View Article and Find Full Text PDF

Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma.

Eur J Clin Pharmacol

December 2024

Center for Pharmacometrics, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Shanghai, 201203, China.

Objectives: This study aimed to quantitatively evaluate the efficacy and safety of first-line systemic therapies for treating advanced hepatocellular carcinoma (aHCC).

Methods: The study included clinical trials of first-line systemic therapies for aHCC since the approval of sorafenib in 2007. Hazard function models were used to describe changes in overall survival (OS) and progression-free survival (PFS) over time.

View Article and Find Full Text PDF

Isoniazid and rifampicin co-therapy are the main causes of anti-tuberculosis drug-induced liver injury (ATB-DILI) and acute liver failure, seriously threatening human health. However, its pathophysiology is not fully elucidated. Growing evidences have shown that fibroblast growth factors (FGFs) play a critical role in diverse aspects of liver pathophysiology.

View Article and Find Full Text PDF

BACKGROUND Ventriculoperitoneal (VP) shunt surgery is a widely used procedure for managing hydrocephalus; however, postoperative infections remain a serious complication, increasing morbidity and mortality. Known risk factors include prior surgeries, steroid use, and concurrent procedures. However, the role of liver cirrhosis, a condition that compromises immune function and predisposes patients to infections, has not been fully investigated in the context of neurosurgery.

View Article and Find Full Text PDF

BACKGROUND Arterioportal fistulas (APFs) are abnormal connections between the arterial and portal venous systems, leading to portal hypertension (PH) and symptoms such as gastrointestinal bleeding, splenomegaly, and hepatic pain. Symptoms typically appear by the age of 2 years in about 75% of cases. CASE REPORT A 7-year-old boy with an asymptomatic APF developed life-threatening complications following a Clostridium difficile infection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!